Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

Inflammatory Bowel Disease V: Surgical Management

Inflammatory Bowel Disease V: Surgical Management

Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Inflammatory Bowel Disease II: Crohn's Disease

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Ocular protection in congenital erythropoietic porphyria: A potential role for gaming glasses.

Photodermatology, photoimmunology & photomedicine·2023

Same author

Photodiagnostic services in the UK and Republic of Ireland: a British Photodermatology Group Workshop Report.

Journal of the European Academy of Dermatology and Venereology : JEADV·2021

Same author

Odontogenic keratocyst located in the retromolar trigone.

Oral surgery, oral medicine, oral pathology and oral radiology·2021

Same author

Characterization of transient noise in Advanced LIGO relevant to gravitational wave signal GW150914.

Classical and quantum gravity·2020

Same author

Palmar digital vein thrombosis in a patient with COVID-19.

Clinical and experimental dermatology·2020

Same author

Winter is coming, and it is going to be tough: COVID-19 and winter preparedness.

Public health·2020

Search research articles

Related Experiment Videos

Superficial granulomatous pyoderma treated preoperatively with infliximab.

V Akhras¹, R Sarkany, S Walsh

¹Department of Dermatology, Maxillofacial Surgery, St George's Hospital, London, UK. vakhras@sgul.ac.uk

Clinical and Experimental Dermatology

|December 20, 2008

Summary

Superficial granulomatous pyoderma (SGP) is a rare skin condition. This case study shows infliximab effectively treated SGP on the face when other immunosuppressants failed.

Related Experiment Videos

Area of Science:

Dermatology
Immunology

Background:

Superficial granulomatous pyoderma (SGP) is a rare, chronic inflammatory skin disease.
Pathergic hypersensitivity reactions can manifest as SGP, often following trauma or surgery.

Observation:

A 71-year-old female presented with facial SGP characterized by erythema, erosions, and cribriform scarring post-eye enucleation.
Histopathology confirmed the typical three-layered granulomas of SGP.
The patient's condition was refractory to multiple conventional immunosuppressive therapies.

Findings:

Successful treatment of recalcitrant facial SGP was achieved with infliximab, a tumor necrosis factor-alpha inhibitor.
Infliximab therapy enabled the patient to proceed with necessary surgical interventions.

Implications:

This case highlights infliximab as a potential therapeutic option for severe, treatment-resistant SGP, particularly on the face.
The findings suggest that anti-TNF therapy may be beneficial in managing pathergic inflammatory conditions like SGP.